NEW YORK (360Dx) – MdxHealth announced today that it has entered into an agency service agreement with Unilabs for MDxHealth's SelectMDx urine test for prostate cancer.

Under the terms of the agreement, Unilabs will offer SelectMDx to patients of all its clinical labs in France, Portugal, Sweden, Norway, Denmark, Finland, UK, Italy, and Switzerland. Unilabs' medical laboratory in Geneva will perform the SelectMDx service testing. To offer the service throughout its network, Unilabs will purchase SelecMDx CE-market IVD kits from MDxHealth.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.